Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil
All cases of ErbB2 positive metastatic breast cancer, receiving approved standard treatment
with lapatinib-capecitabine, after trastuzumab-containing regimen progression in community
setting can participate in this observational study, for a period of 12 months of
observation since the start of the lapatinib-capecitabine treatment.
Observational
Observational Model: Cohort, Time Perspective: Prospective
Time to disease progression (TTP)
Time from the date of start of Lapatinib-capecitabine treatment until date of documented disease progression by the treating physician, determined by clinical and/or radiological assessment
One year
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
Brazil: Institutional Review Board
113960
NCT01357863
July 2010
February 2011
Name | Location |
---|